Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Gallagher

Showing results (41-50 of 797) with videos related to

Pageof 80
Sort By:
Anticancer Research|July 1, 1994
The ability of transforming growth factor-beta 1 to preferentially inhibit the induction of cytotoxicity in human T cells is determined by the nature of the activating signalsJ Xie, G Gallagher
Anticancer Research|November 1, 1992
Transforming growth factor-beta is not the major soluble immunosuppressor in the microenvironments of human breast tumoursJ Xie, G Gallagher
Immunology|October 1, 1994
The in vivo production of specific human antibodies by vaccination of human-PBL-SCID miceW Walker, G Gallagher
Journal of Gerontological Nursing|December 1, 1993
Patient Self-Determination Act. Implementing an information program in a nursing facilityM Drugay, G Gallagher
Surgical Oncology|January 1, 1993
Co-stimulation with IL-2, but not via CD28, overcomes immunosuppression by breast tumour-derived factors on the in vitro stimulation of human T-cellsJ Xie, G Gallagher
FEMS Yeast Research|November 17, 2018
Proteins and RNA sequences required for the transition of the t-Utp complex into the SSU processomeJennifer E G Gallagher
Immunogenetics|January 1, 1995
A polymorphic dinucleotide repeat in the human IL-10 promoterJ Eskdale, G Gallagher
Clinical and Experimental Immunology|September 1, 1995
The development of a novel immunotherapy model of human ovarian cancer in human PBL-severe combined immunodeficient (SCID) miceW Walker, G Gallagher
Anticancer Research|July 1, 1993
IL-2 inhibits the induction of systemic antitumour immunity by IL-4 in the peritumoural treatment of experimental melanomaY Zaloom, G Gallagher
BMJ (Clinical Research Ed.)|September 28, 1991
Doctors and dropsG Gallagher, I Mackay
Pageof 80

Showing results (41-50 of 797) with videos related to

Sort By:
Pageof 80
Anticancer Research|July 1, 1994
The ability of transforming growth factor-beta 1 to preferentially inhibit the induction of cytotoxicity in human T cells is determined by the nature of the activating signalsJ Xie, G Gallagher
Anticancer Research|November 1, 1992
Transforming growth factor-beta is not the major soluble immunosuppressor in the microenvironments of human breast tumoursJ Xie, G Gallagher
Immunology|October 1, 1994
The in vivo production of specific human antibodies by vaccination of human-PBL-SCID miceW Walker, G Gallagher
Journal of Gerontological Nursing|December 1, 1993
Patient Self-Determination Act. Implementing an information program in a nursing facilityM Drugay, G Gallagher
Surgical Oncology|January 1, 1993
Co-stimulation with IL-2, but not via CD28, overcomes immunosuppression by breast tumour-derived factors on the in vitro stimulation of human T-cellsJ Xie, G Gallagher
FEMS Yeast Research|November 17, 2018
Proteins and RNA sequences required for the transition of the t-Utp complex into the SSU processomeJennifer E G Gallagher
Immunogenetics|January 1, 1995
A polymorphic dinucleotide repeat in the human IL-10 promoterJ Eskdale, G Gallagher
Clinical and Experimental Immunology|September 1, 1995
The development of a novel immunotherapy model of human ovarian cancer in human PBL-severe combined immunodeficient (SCID) miceW Walker, G Gallagher
Anticancer Research|July 1, 1993
IL-2 inhibits the induction of systemic antitumour immunity by IL-4 in the peritumoural treatment of experimental melanomaY Zaloom, G Gallagher
BMJ (Clinical Research Ed.)|September 28, 1991
Doctors and dropsG Gallagher, I Mackay
Pageof 80